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Abstract 
A stability indicating HPLC assay method has been developed and validated for the estimation of aprepitant in bulk and 
pharmaceutical dosage forms. A RP-HPLC isocratic separation was achieved on C18 column (250X4.6 mm i.d., 5µm) utilizing 
a mobile phase comprising of methanol and water in the ratio of 90: 10(v/v) and the eluents from the column were detected 
using a variable wavelength detector at 220 nm. The stress testing of aprepitant was carried out under acidic, alkaline 
hydrolysis, oxidation and thermal degradation (dry heat) conditions and apripitant was well resolved from its degradation 
products with good resolution. The proposed method has permitted the quantification of aprepitant in the linearity range of 1-
100µg/ml and the flow rate was maintained at 1ml/min. The column was maintained at ambient temperature and the complete 
separation was achieved for aprepitant with all degradation products in an overall analytical run time of approximately 15 min 
and it was eluting at approximately 4.4 min. The retention times of aprepitant and rimonabant hydrochloride (IS) were found to 
be 4.383 min and 5.783 min, respectively. The limit of detection and limit quantification were found to be 0.130µg/ml and 
0.395µg/ml, respectively. The percentage recovery was found to be in between 99.56 to 101.5 and the % RSD of system and 
method precision was found to be 1.20 and 0.561, respectively. The percentage amount of marketed commercial brand of 
aprepitant was found to be 99.97. The method was found to be suitable for the routine quality control analysis of aprepitant in 
bulk drug and formulation as well as for the stability indicating studies. The method was validated as per ICH guidelines. 
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Introduction 
Aprepitant (APT) is a substance P (SP) / 
neurokinin 1 (NK1) receptor antagonist and chemically 
described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-
bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4- 
morpholinyl]methyl]-1,2dihydro-3H-1,2,4-triazol-3-one 
(fig.1).  It is a white to off-white crystalline solid, with a 
molecular weight of 534.43 and empirical formula of 
C23H21F7N4O3. APT is a selective high affinity 
antagonist of human substance P/neurokinin 1 (NK1) 
receptors and it has little or no affinity for serotonin (5-
HT3), dopamine, and corticosteroid receptors. A large 
number of drugs are available for prevention of PONV 
[1], of which 5-HT3 receptor antagonists have occupied 
an important position because of their better efficacy 
and side effect profile with a disadvantage that it 
prevents only acute emesis. A newer class of drugs 
namely neurokinin receptor antagonists provides an 
additional advantage of preventing both acute and 
delayed emesis. Various NK1 receptor antagonists 
studied include APT, GR-205171, CP-122721 and CJ-
11974, of which APT has been approved for PONV 
and treatment of nausea in cancer chemotherapy. APT 
has been shown in animal models to inhibit emesis 
induced by cytotoxic chemotherapeutic agents, such as 
cisplatin, via central actions. Animal and human 
Positron Emission Tomography (PET) studies with APT 
have shown that it crosses the blood brain barrier and 
occupies brain NK1 receptors [2] and also showed that 
APT augments the antiemetic activity of the 5-HT3 
receptor antagonist ondansetron and the corticosteroid 
dexamethasone and inhibits both the acute and 
delayed phases of cisplatin-induced emesis. It has 
been recently demonstrated that substance P (SP) and 
neuro kinin -1 (NK1) receptor antagonists induce cell 
proliferation and cell inhibition in human melanoma 
cells. Literature review reveals that very few analytical 
methods has been established for the estimation of 
APT in human plasma [3] and estimation of its 
metabolites in human plasma [4], HPLC 
chromatographic reactor approach for investigating the 
hydrolytic stability of a pharmaceutical compound [5], 
estimation of APT in rhesus macaque plasma [6], 
characterization and quantitation of APT drug 
substance polymorphs by attenuated total reflectance 
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fourier transform infrared spectroscopy [7], stability of 
an extemporaneous oral liquid APT formulation [8] , 
estimation of APT capsules by RP-HPLC [9] were 
reported.  
 
   Fig 1: Chemical structure of Aprepitant 
 
 
 
 
 
 
 
The stability of a drug substance or drug product 
is defined as its capacity to remain within established 
specifications, i.e. to maintain its identity, strength, 
quality, and purity until the retest or expiry date [10]. 
Stability testing of an active substance or finished 
product provides evidence of how the quality of a drug 
substance or drug product varies with time under a 
variety of environmental conditions, for example 
temperature, humidity, and light. Knowledge from 
stability studies is used in the development of 
manufacturing processes, selection of proper 
packaging and storage conditions, and determination 
of product shelf-life [11, 12]. Only one method was 
reported for the determination of APT in presence of its 
degradation products in oral liquid formulation in the 
literature. But there was no reported stability-indicating 
analytical method for analysis of APT in the presence 
of its degradation products in bulk and pharmaceutical 
dosage forms. The objective of this work was to 
develop a new, simple, economic, rapid, precise, and 
accurate stability-indicating HPLC method for 
quantitative analysis of APT, and to validate the 
method in accordance with ICH guidelines [13] with 
rimonabant hydrochloride as an internal standard 
showed advantages of shorter retention time, runtime, 
and economic mobile phase.  
 
Experimental 
Materials 
Pure standard of APT (Assigned purity 99.96%) 
was obtained as a gift sample from Dr.Reddys 
laboratories Pvt. Ltd, Hyderabad and pure sample of 
rimonabant hydrochloride (IS, assigned purity 99.87%) 
was obtained from Inventis drug delivery systems, Pvt. 
Ltd, Hyderabad along with certificate of analysis (COA). 
HPLC grade water and methanol (Qualigens), 
Hydrochloric acid, Sodium hydroxide, Hydrogen 
peroxide (S.D. fine chemicals, Mumbai, India), Hot air 
oven (Sky lab instruments & engineering Pvt. Ltd) 
Electronic analytical balance (DONA), Micro pipette (In 
labs, 10-100µl) and Aprecap capsules (80 mg, Glen 
mark pharmaceuticals Ltd) were employed in the study. 
All the glassware employed in the study was cleaned 
with hot water, followed by acetic anhydride and then 
with acetone and dried in hot air oven when ever 
required. Working environment was maintained in 
between 18-220c. However, the chemical structure and 
purity of the sample obtained were confirmed by TLC, 
IR, Melting point, DSC studies. 
 
Instrumentation and chromatographic conditions 
A HPLC system consisted of an Agilent LC 1200 
HPLC pump, solvent degasser, a variable wavelength 
detector with deuterium lamp, a rheodyne injector and 
EZ chrom elite soft ware. Isocratic elution of mobile 
phase comprising of methanol and water in the ratio of 
90: 10(v/v) with flow rate of 1ml/min was performed on 
C18 column (250x 4.6 mm i.d., 5µm). The column 
temperature was maintained at ambient and the 
volume of injection was 20 μl. Prior to injection of 
analyte, the column was equilibrated for 30-40 min with 
mobile phase. The eluents were monitored at 220 nm, 
data were acquired, stored and analysed with soft ware 
EZ chrom elite.  
 
Preparation of mobile phase  
The HPLC grade solvents of methanol and water 
were used for the preparation of mobile phase in the 
ratio of 90:10 (v/v). The contents of the mobile phase 
were filtered before use through a 0.45µm membrane 
filter, sonicated and pumped from the solvent reservoir 
to the column at a flow rate of 1 ml/min.  
 
Procedure recommended  
Preparation of standard solution 
A stock solution of drug and internal standard (IS) 
was prepared by dissolving 100 mg of APT and 
rimonabant hydrochloride in a 100 ml volumetric flasks 
containing 70 ml of methanol (HPLC grade), sonicated 
for about 15 min and then made up to volume with 
methanol. Daily working standard solutions of APT and 
rimonabant hydrochloride were prepared by suitable 
dilution of the stock solution with the mobile phase. Six 
sets of the drug solution were prepared in the mobile 
phase containing APT at a concentration of 1-
100µg/ml along with a fixed concentration (0.4µg/ml) 
of rimonabant hydrochloride as the internal standard. 
Each of these drug solutions (20µl) was injected six 
times into the column, the peak area and retention 
times were recorded. 
 
Procedure for pharmaceutical formulation  
Twenty capsules were weighed and the contents 
were removed to obtain the average weight powder. A 
sample of the powder equivalent to 100 mg of the 
active ingredient was mixed with known amount of 
methanol and the mixture was allowed to stand for 30 
min with intermittent sonication to ensure complete 
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solubility of the drug, then it was filtered through a 0.45 
µm membrane filter, followed by adding methanol to 
obtain a stock solution of 0.1 mg/ml (100µg/ml).  An 
aliquot of this solution (1 ml) was transferred to a 10 ml 
volumetric flask and made up to a sufficient volume 
with the mobile phase to give an expected 
concentration of 10 µg/ml. All determinations were 
conducted in triplicate. 
 
Forced degradation of API and capsules of APT 
In order to establish whether the analytical method 
and the assay were stability indicating, the capsules 
and pure active pharmaceutical ingredient of APT were 
stressed under various conditions to promote 
degradation. As this drug was freely soluble and stable 
in methanol and methanol was used as solvent in all 
forced degradation studies. All solutions were prepared 
to use in forced degradation studies were prepared by 
dissolving API or drug product in small volume 
methanol and later diluted with 3% hydrogen peroxide, 
0.1 N hydrochloric acid and 0.1 N sodium hydroxide to 
achieve concentration of 100 μg/ml. After the 
degradation, these solutions were diluted with mobile 
phase to get starting concentration of 10μg/ml with the 
objective of evaluating stability of APT. The degradants 
were observed in the chromatogram and showing good 
resolution with the APT.  
 
Hydrolysis (Acid and alkali) 
Initially for hydrolytic degradation the APT was 
dissolved in known amount of methanol and diluted 
with 0.1N HCl or 0.1N NaOH to obtain a concentration 
of 100µg/ml. After completion of degradation process, 
both the solutions were neutralized with acid or base, 
as necessary and diluted with the mobile phase to 
achieve a concentration of 10µg/ml. The solutions for 
hydrolysis were prepared in methanol and 0.1 N HCl 
and 0.1N NaOH (60:40 v/v). The prepared solutions in 
acid were injected to the chromatographic system at 0 
h (immediately after preparing the solution) and after 
reflux at 600c about 2h and the solutions prepared in 
alkali were injected at 0 h and after reflux at 600c about 
24 h. The respective chromatograms were recorded for 
the study of extent of degradation. 
 
Peroxide degradation  
The solutions for peroxide degradation were 
prepared in methanol and 3% hydrogen peroxide 
(60:40 v/v). The prepared solution was refluxed at 600c 
about 2h and injected into chromatographic system 
after 2 h. The respective chromatogram was recorded 
for the study of extent of degradation. 
 
Thermal degradation 
The bulk and marketed formulation was subjected 
to heat treatment for the assessment of the thermal 
degradation and were exposed to dry heat in an oven 
at 700c about two days (48h).The capsules and bulk 
drug was removed from the oven and the contents of 
capsule were collected and mixed. The amount which 
was equivalent to 100 mg of active ingredient and bulk 
drug were prepared for analysis by the proposed 
method. The respective chromatograms were recorded 
for the study of extent of degradation. 
 
Results and Discussions  
Optimization of chromatographic conditions 
(method development) 
A simple stability-indicating RP-HPLC method has 
been developed for determination of APT in presence 
of its degradation products. The method was optimized 
to provide a good separation of the components 
(acceptable theoretical plates and resolution between 
peaks) with a sufficient sensitivity and suitable peak 
symmetry (peak tailing factor < 2) in a short run. For 
this purpose, the analytical column, solvent selection, 
mobile phase composition, flow rate, and detector 
wavelength were studied. The use of hydrophobic 
stationary phases usually provides adequate retention 
of organic non polar molecules. The chromatographic 
separation was achieved using an RP C18 column 
because it was suitable to resolve the degradation 
products from APT with adequate resolution and gave 
symmetrical peak shapes. APT was easily soluble in 
methanol and it is a well known solvent for various 
pharmaceutical compounds. Data reported in the 
literature showed that 0.01 M ammonium Acetate 
containing 0.1% formic acid and methanol in the ratio 
of 35:65 v/v was used a mobile phase. But our 
experiments using methanol used along with water 
(HPLC grade) as mobile phase was eluted the APT in 
a significant shorter retention time of 4.383 min. 
Therefore, we selected methanol and water in the ratio 
of 90:10 (v/v) as a mobile phase. The method has 
many advantages, e.g., simplicity, isocratic conditions, 
and absence of buffers in the mobile phase that could 
damage the chromatographic column and equipment. 
Under these conditions, the retention time of APT was 
about 4.383 min, with a good peak shape (peak 
symmetry).  
Stability indicating method development  
Solutions used in forced degradation studies were 
prepared by dissolving API and drug formulation in 
small volumes of methanol and then diluting with 3% 
aqueous hydrogen peroxide, 0.1 N aqueous 
hydrochloric acid, and 0.1 N aqueous sodium 
hydroxide to promote degradation at concentration of 
100µg/ml of APT. After degradation at suitable 
degradation conditions the samples were diluted with 
mobile phase and subjected to HPLC analysis. To 
study the effect of thermal stress, Aprecap capsules 
and API powder were exposed to dry heat at 700c in a 
convection oven for about 48 h. The samples removed 
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from the oven, the contents from the twenty capsules 
were removed, thoroughly mixed and the average 
weight calculated. Equivalent amount of powder was 
analysed after preparation of 10 µg/ml solutions in 
mobile phase. Chromatograms for all samples were 
inspected for the appearance of additional peaks and 
the APT peak was compared between samples for 
changes in concentration, retention time, peak shape, 
and UV spectral purity compared to an authentic 
undegraded standard. The degradant were well 
resolved from the APT, shows that the assay was 
stability indicating and specific. 
 
Method validation  
The method was validated as per the ICH 
guidelines for different validation parameters. The 
method was validated for its specificity, linearity, 
accuracy, precision, selectivity, LOD and LOQ. 
 
Specificity  
The results from the stress studies indicated that 
the method was highly specific for APT. The 
degradation products were completely distinguishable 
from the parent compound. Based on peak purity of 
APT, every degradation sample showed that the peaks 
were homogenous and there were no co eluting peaks 
indicating that the method was stability indicating and 
specific. 
 
Linearity  
The standard plot for the APT was constructed by 
plotting the ratio of the peak area of APT to the peak 
area of the internal standard (Y) against concentration 
(X). It was found to be linear with a correlation 
coefficient (r2) of 0.999, the corresponding linear 
regression equation being y=0.288x + 0.32. In the 
linear range of 1-100µg/ml, the coefficients of variation 
(CV) based on the peak area ratios for six replicate 
injections, were found to be in between  0.16 to 0.72. 
 
Statistical data of calibration curves  
The regression characteristics, such as standard 
deviation of slope (Sb, 0.029), the % RSD of the slope 
(11.12), the standard deviation of intercept (Sa, 0.0576), 
regression equation (0.288x + 0.32) and correlation 
coefficient (r2, 0.999) were calculated. 
 
Precision  
Precision is the measure of how close the data 
values to each other for a number of measurements 
under the same analytical conditions. Six replicate 
measurements/injections of standard preparation 
(System Precision), six replicate analysis of the 
samples through the complete analytical procedure 
from sample preparation (Method Precision) was 
performed. The % RSD of system precision and 
method precision were found to be 1.20 and 0.561, 
respectively and were shown in the table-1.
 
                                                                                   Table 1: Precision of the method 
 
S.No System precision Method precision 
1 8880239 100.3 
2 8634069 99.84 
3 8852531 100.5 
4 8760932 99.97 
5 8823094 98.93 
6 8645867 99.56 
Mean (n=6) 8766122 99.85 
%RSD 1.20 0.561 
 
Accuracy  
To ensure the reliability and accuracy of the 
method, the recovery studies were carried out by 
adding a known quantity of drug with preanalysed 
sample and contents were reanalyzed by the proposed 
method. Accuracy was evaluated by injecting five times 
at three different concentrations equivalent to 80, 100, 
and 120% of the active ingredient, by adding a known 
amount of APT standard to a sample of known 
concentration and calculating the recovery of APT with 
RSD (%) and % recovery for each concentration. The 
mean % recoveries were in between 99.56 to 101.5 
and shown in table -2. There was a high recovery 
101.5% of APT indicating that the proposed method for 
the determination of APT in the capsule dosage forms 
was highly accurate.
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Table 2: Accuracy of the method 
APT 80% level 100% level 120% level 
1 99.56 100.2 101.5 
2 101.32 99.97 100.4 
3 100.76 99.56 100.2 
Mean (n=3) 100.54 99.91 100.7 
% RSD 0.899 0.324 0.7 
 
System suitability  
To know reproducibility of the method system 
suitability test was employed to establish the 
parameters such as tailing factor, theoretical plates, 
resolution, asymmetry factor, and asymmetry (10%), 
limit of detection and limit of quantification. The values 
were shown in table-3.
  
Table 3: System suitability   
Parameter Value 
Retention time (min) 4.383  
Theoretical plates 1230 
Tailing factor  1.25 
Linearity range (µg/ml) 1-100 
Limit of detection (µg/ml) 0.130 
Limit of quantification(µg/ml) 0.395 
Resolution  3.5 
Asymmetry factor 1.22 
Asymmetry (10%) 1.18 
       
Selectivity  
The results of stress testing studies indicated a 
high degree of selectivity of this method for APT. The 
degradation of APT was found to be similar for both the 
capsules and API powder.  
 
Limit of detection (LOD) and quantification (LOQ) 
The limits of detection and quantification were 
calculated by the method based on standard deviation 
(σ) of responses for triplicate blank injections and the 
slope (S) of the calibration plot, using the formulae 
 and  as defined 
by ICH. 
 
Stress degradation studies  
To determine whether the method was stability 
indicating, APT capsules and APT active 
pharmaceutical ingredient (API) powder were stressed 
under different conditions to promote degradation. 
Regulatory guidance in ICH Q2A, Q2B, Q3B and FDA 
21 CFR section 211 requires the development and 
validation of stability indicating potency assays. APT 
was exposed to different stress conditions and the 
degradation products were well separated with greater 
resolution. The drug was showed degradation in all 
degradation conditions .The drug was degraded in both 
acidic and alkali environments when it was exposed to 
0.1N HCl (at 0h, 2 h) and 0.1N NaOH (at 0 h, 24h). In 
acidic degradation of APT at 0 h (immediately after 
preparing the solution) had shown 2 degradation 
products with the retention times (2.967 and 3.813 min) 
and the APT was eluted at retention time of 4.4 min 
with percentage of degradation 30.85. After reflux at 
600c for about 2 h, APT had shown 8 degradation 
products with retention times (1.530, 2.960, 3.440, 
3.650, 3.783, 5.257, 5.810, and 6.193 min) and the 
APT was eluted at retention time of 4.397min with 
percentage of degradation 32.52. In alkali degradation 
of drug at 0 h (immediately after preparing the solution) 
had shown 2 degradation products with the retention 
times (2.963 and 3.780 min) and the APT was eluted at 
retention time of 4.393 min with percent of degradation 
23.7. After reflux at 600c for about 24 h the APT had 
shown six degradation products with retention times 
(2.400, 2.973, 3.223, 3.523, 3.873 and 5.613 min) and 
the drug was eluted with the retention time of 4.623 
min with percentage of degradation 47.16. After reflux 
at 600c for about 2h in hydrogen peroxide the APT was 
completely degraded with 100% degradation. The 
degradation was observed in thermal treatment of APT 
for about 48 hr at 700 c in an oven (dry heat) and the 
API and capsule had shown degradation about 31.31% 
and 25.03%, respectively. The degradation of bulk had 
shown eight degradants with retention times (2.407, 
3.047, 3.693, 3.917, 4.043, 5.293, 5.743 and 6.233 min) 
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and the APT was eluted at 4.603 min. The degradation 
of APT capsule had shown seven degradants with 
retention times (2.507, 3.060, 3.630, 4.383, 4.670, 
5.530, and 6.810 min) and the APT was eluted 4.670 
min. The percentage of degradation and the summary 
of forced degradation data were shown in the table-4, 5 
and the chromatograms of degraded APT in different 
stress conditions were shown in fig.2 (a-g).
  
Table 4:  % of degradation  
 
Degradation 
mechanism Degradation condition 
Assay 
(mg/tab) % Degradation 
Un degraded - 79.98 - 
Acid hydrolysis 0.1 N HCl, at 0 hr, 2hr 55.94, 53.97 30.05%, 32.52% 
Alkali hydrolysis 0.1 N NaOH, at 0 hr, 24 hr 61.02, 42.26 23.7%, 47.16% 
H2O2 oxidation 3% H2O2 at 2 hr --------- 100% 
Thermal solid Dry heat, 48 hrs in oven 54.93 31.31% 
Thermal liquid Dry heat 48 hrs in oven 59.96 25.03% 
                                             
   Table 5:  Forced degradation of APT 
 
S.No Exposure condition Degradation Products (Rt, in min) 
%Drug 
remained 
% 
recovery Fig no 
1 
0.1N HCl at 0 h& 
after reflux at 600c 
about 2h 
2 (2.967 and  3.813) 69.95 67.48 
69.95    
67.48 
2(a) 
2(b) 
2 
0.1 N NaOH at 0 h& 
after reflux at 600c 
about 24h 
8 (1.530, 2.960, 
3.440, 3.650, 3.783, 
5.257, 5.810 and 
6.193) 
76.30 
 52.84 
76.30 
52.84 
2 (c) 
2(d) 
3 
H2O2 (3% v/v), after 
reflux at 600c about 
2h 
------------------------ 0                
 
0 
 
 
2(e) 
 
4 
Thermal  treatment 
of API at 700 C 
about 48 h in an 
oven 
8 ( 2.407, 3.047, 
3.693, 3.917, 4.043, 
5.293, 5.743 and 
6.233) 
68.69  68.69 2(f)  
5 
Thermal  treatment 
of API capsule at 
700 C about 48h in 
an oven 
7 ( 2.507, 3.060, 
3.630, 4.383, 4.670, 
5.530 and 6.810) 
74.97 74.97 2(g) 
 
Fig 2 (a):  A Chromatogram of APT degraded in 0.1 N HCl at 0 h  
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 2(b): A Chromatogram of APT degraded in 0.1 N HCl after reflux at 600c about 2 hr 
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 Fig 2(c): A Chromatogram of APT degraded in 0.1 N NaOH at 0 h 
 
 
 
 
 
 
 
 
 
 
 
   Fig 2(d): A Chromatogram of APT degraded in 0.1 N NaOH after reflux at 600c about 24 h 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 2(e): A Chromatogram of APT degraded in 3% H2 O2 after reflux at 600c about 2 h 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Fig 2(f):  A Chromatogram of API degraded in an oven at 700c about 48 h  
 
 
 
 
 
 
 
 
 
 
 
 Fig 2(g): A Chromatogram of capsule of APT degraded in an oven at 700c about 48 h 
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Estimation of APT in marketed capsule formulation  
The assay of commercial capsules was 
established with present chromatographic condition 
developed and it was found to be more accurate and 
reliable. The average drug content was found to be 
99.97 of the labeled claim. No interference peaks were 
found in chromatogram, indicating that estimation of 
APT free from interference of excipients. The results 
were shown in the table-6 and the chromatograms of 
APT with internal standard were shown in fig. 3, 4. 
 
 
Table 5: Assay of the method  
Brand name Labeled claim Mean amount found*± S.D % purity 
Aprecap 80 mg 79.976±0.12 99.97 
                                  *Mean of three values  
 
Fig 3: A typical chromatogram of APT with rimonabant hydrochloride (IS) 
 
 
 
 
 
 
 
 
  Fig 4: A typical chromatogram of APT capsule with rimonabant hydrochloride (IS) 
 
 
 
 
 
 
 
 
 
  
Conclusion 
A validated stability-indicating HPLC analytical 
method has been developed for the determination of 
APT in API and dosage forms. The results of stress 
testing undertaken according to the International 
Conference on Harmonization (ICH) guidelines reveal 
that the method was selective and stability-indicating. 
The proposed method was simple, accurate, precise, 
specific, and has the ability to separate the drug from 
degradation products. In the absence of a stability 
indicating assay in the literature, the proposed method 
was suitable to use for the routine analysis of APT in 
either bulk API powder or in pharmaceutical dosage 
forms. The simplicity of the method allows for 
application in laboratories that lack sophisticated 
analytical instruments such as LC–MS and or GC–MS. 
These methods are complicated, costly and time 
consuming rather than a simple HPLC-UV method. In 
addition, the HPLC procedure can be applied to the 
analysis of samples obtained during accelerated 
stability experiments to predict expiry dates of 
pharmaceuticals. The method had proved its 
importance in terms of sensitivity, rapidity, economy in 
the stability indicating estimation of APT. 
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